ISPOR 2016 EU – Value Added Medicines

ispor2

Healthcare System Inefficiencies Related To Medicines: Any Potential Room For Improvement?

ispor3

Value Added Medicines: The Need to Establish One Common Terminology for Repurposed Medicines

ispor4

Value Added Medicines: What Value Repurposed Medicines Might Bring to Society?

ispor5

Obstacles for Adoption of Value Added Medicines: Call for Policy Changes for Value Recognition of Repurposed Medicines

Giving medicines a new life: EU should foster patients’… 30 November 2022 The added value of innovating on existing medicines may be…
OPEN LETTER: Members of the European Parliament and EU 27… 8 November 2023 Medicines for Europe, the European association representing generic, biosimilar and…
Time for the EU to take steps: a medicines security act is… 2 October 2023 The off-patent medicines industry provides 70% of medicines dispensed to…
Spanish Presidency set to advance medicines supply… 4 July 2023 The EU pharmaceutical strategy aims to improve accessibility, affordability and…